title: Can Cannabinoids Modulate Fibrotic Progression in Systemic Sclerosis?
authors.forename: Estrella
authors.initials: E
authors.lastname: Garcia-Gonzalez
authors.forename: Mauro
authors.initials: M
authors.lastname: Galeazzi
authors.forename: Enrico
authors.initials: E
authors.lastname: Selvi
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D063385:Cannabinoid Receptor Modulators / Q000494:pharmacology; D002186:Cannabinoids / Q000276:immunology / Q000494:pharmacology; D003238:Connective Tissue / Q000473:pathology; D004195:Disease Models, Animal; D018450:Disease Progression; D063388:Endocannabinoids / Q000276:immunology; D005355:Fibrosis / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology / Q000494:pharmacology; D051379:Mice; D047495:PPAR gamma / Q000037:antagonists & inhibitors / Q000378:metabolism; D043882:Receptors, Cannabinoid / Q000276:immunology; D012595:Scleroderma, Systemic / Q000276:immunology / Q000473:pathology / Q000503:physiopathology
chemical_list: D000893:Anti-Inflammatory Agents; D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids; D063388:Endocannabinoids; D007155:Immunologic Factors; D047495:PPAR gamma; D043882:Receptors, Cannabinoid